Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Miguel Ángel Rodríguez-Milla"'
Autor:
Patricia Garcia-Rodriguez, Laura Hidalgo, Miguel Angel Rodriguez-Milla, Beatriz Somovilla-Crespo, Javier Garcia-Castro
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
LIN28, a highly conserved RNA-binding protein that acts as a posttranscriptional modulator, plays a vital role in the regulation of T-cell development, reprogramming, and immune activity in infectious diseases and T-cell-based immunotherapies. LIN28
Externí odkaz:
https://doaj.org/article/89d80d6b3c594a39b5f7cbec3a69c473
Autor:
Miguel Ángel Rodríguez-Milla, Ana Judith Perisé-Barrios, Alvaro Morales-Molina, Javier García-Castro, Teresa Cejalvo
Publikováno v:
Cancer Gene Therapy. 28:64-73
Factor de impacto: 5,987 Q1 There is increasing evidence about the use of oncolytic adenoviruses (Ads) as promising immunotherapy agents. We have previously demonstrated the clinical efficiency of mesenchymal stem cells (MSCs) infected with oncolytic
Autor:
Alvaro Morales-Molina, Miguel Angel Rodriguez-Milla, Patricia Garcia-Rodriguez, Laura Hidalgo, Ramon Alemany, Javier Garcia-Castro
Publikováno v:
Molecular Therapy: Oncology, Vol 32, Iss 3, Pp 200863- (2024)
Oncolytic viruses often face challenges in achieving optimal antitumor immunity as standalone therapies. The penton base RGD-integrin interactions play a significant role in wild-type adenovirus-induced innate immune responses. To modify these respon
Externí odkaz:
https://doaj.org/article/f889f634fb8d45d19137a418f077a9bb
Autor:
Javier García-Castro, Ana Judith Perisé-Barrios, Alvaro Morales-Molina, Alicia Gimenez-Sanchez, Miguel Ángel Rodríguez-Milla
Publikováno v:
Repisalud
Instituto de Salud Carlos III (ISCIII)
Cancers
Volume 12
Issue 7
Cancers, Vol 12, Iss 1920, p 1920 (2020)
Instituto de Salud Carlos III (ISCIII)
Cancers
Volume 12
Issue 7
Cancers, Vol 12, Iss 1920, p 1920 (2020)
Oncolytic virotherapy uses viruses designed to selectively replicate in cancer cells. An alternative to intratumoral administration is to use mesenchymal stem cells (MSCs) to transport the oncolytic viruses to the tumor site. Following this strategy,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a44d320e6ca80a91c7eb478c509d0de4
https://hdl.handle.net/20.500.12105/10846
https://hdl.handle.net/20.500.12105/10846
Autor:
Alvaro, Morales-Molina, Miguel Ángel, Rodríguez-Milla, Alicia, Gimenez-Sanchez, Ana Judith, Perisé-Barrios, Javier, García-Castro
Publikováno v:
Cancers
Oncolytic virotherapy uses viruses designed to selectively replicate in cancer cells. An alternative to intratumoral administration is to use mesenchymal stem cells (MSCs) to transport the oncolytic viruses to the tumor site. Following this strategy,
Autor:
Gisèle Bonne, Anne Bertrand, Carolina Epifano, Javier Ramón-Azcón, Alberto Martín, Albert G. Castaño, Miguel Ángel Rodríguez-Milla, Déborah Gómez-Domínguez, Fernando de Miguel, Borja Vilaplana-Martí, Sandra Amarilla-Quintana, Ignacio Pérez de Castro
Publikováno v:
Cells
Repisalud
Instituto de Salud Carlos III (ISCIII)
Cells, MDPI, 2020, 9 (5), pp.1286. ⟨10.3390/cells9051286⟩
Cells, Vol 9, Iss 1286, p 1286 (2020)
ABACUS. Repositorio de Producción Científica
Universidad Europea (UEM)
Volume 9
Issue 5
Repisalud
Instituto de Salud Carlos III (ISCIII)
Cells, MDPI, 2020, 9 (5), pp.1286. ⟨10.3390/cells9051286⟩
Cells, Vol 9, Iss 1286, p 1286 (2020)
ABACUS. Repositorio de Producción Científica
Universidad Europea (UEM)
Volume 9
Issue 5
Laminopathies are causally associated with mutations on the Lamin A/C gene (LMNA). To date, more than 400 mutations in LMNA have been reported in patients. These mutations are widely distributed throughout the entire gene and are associated with a wi
Autor:
Ana Judith Perisé-Barrios, Miguel Ángel Rodríguez-Milla, Stefano Gambera, Javier García-Castro, Alvaro Morales-Molina, Teresa Cejalvo, Rafael Moreno
Publikováno v:
Repisalud
Instituto de Salud Carlos III (ISCIII)
Instituto de Salud Carlos III (ISCIII)
Factor de impacto: 6,968 Q1 Oncolytic virotherapy uses oncolytic viruses that selectively replicate in cancer cells. The use of cellular vehicles with migration ability to tumors has been considered to increase their delivery to target sites. Followi
Autor:
Francisca Mulero, Rene Rodriguez, Ander Abarrategi, Miguel Ángel Rodríguez-Milla, Stefano Gambera, Javier García-Castro, Sofía T. Menéndez, Samuel Navarro
Publikováno v:
Scopus
RUO. Repositorio Institucional de la Universidad de Oviedo
instname
STEM CELLS
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
RUO. Repositorio Institucional de la Universidad de Oviedo
instname
STEM CELLS
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Osteosarcoma (OS) is a highly aggressive bone tumor that usually arises intramedullary at the extremities of long bones. Due to the fact that the peak of incidence is in the growth spurt of adolescence, the specific anatomical location, and the heter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e800ab81ca7ad765680d3b10b4c4c81e
http://hdl.handle.net/10651/49920
http://hdl.handle.net/10651/49920
Autor:
Francisca Mulero, Probir Chakravarty, Alexander Waclawiczek, Raquel Pérez-Tavarez, Miguel Ángel Rodríguez-Milla, Ander Abarrategi, Stefano Gambera, Kevin Rouault-Pierre, Javier García-Castro, Arantzazu Alfranca, Cesar Trigueros, Samuel Navarro, Dominique Bonnet
Publikováno v:
Scientific Reports
Scientific Reports, Vol 8, Iss 1, Pp 1-13 (2018)
Repisalud
Instituto de Salud Carlos III (ISCIII)
Scientific Reports, Vol 8, Iss 1, Pp 1-13 (2018)
Repisalud
Instituto de Salud Carlos III (ISCIII)
Mesenchymal progenitor cells (MPCs) have been hypothesized as cells of origin for sarcomas, and c-Fos transcription factor has been showed to act as an oncogene in bone tumors. In this study, we show c-Fos is present in most sarcomas with chondral ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc78b1ec261665bb94fa3689bb69d0cf
https://hdl.handle.net/20.500.12105/9136
https://hdl.handle.net/20.500.12105/9136
Autor:
Noemí del Castillo, Eduardo Laborda, Ramon Alemany, Isabel Cubillo, Fernando León Vázquez, Manuel Ramírez, Miguel Ángel Rodríguez-Milla, Javier García-Castro, David Sardón, Isabel del Portillo, Ana Judith Perisé-Barrios, Teresa Cejalvo
Publikováno v:
Repisalud
Instituto de Salud Carlos III (ISCIII)
Instituto de Salud Carlos III (ISCIII)
Dogs with spontaneous tumors treated in veterinary hospitals offer an excellent opportunity for studying immunotherapies, including oncolytic viruses. Oncolytic viruses have advanced into the clinic as an intratumorally administered therapeutic; howe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dfa2339ab18889c865572895e26e097
http://hdl.handle.net/20.500.12105/10620
http://hdl.handle.net/20.500.12105/10620